Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
80.80
-0.30 (-0.37%)
Mar 3, 2026, 1:30 PM CST
-28.50%
Market Cap 9.94B
Revenue (ttm) 37.46M
Net Income (ttm) -88.37M
Shares Out 122.62M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 255,690
Average Volume 219,511
Open 81.10
Previous Close 81.10
Day's Range 79.60 - 81.60
52-Week Range 70.10 - 118.00
Beta -0.04
RSI 59.50
Earnings Date Mar 17, 2026

About Gongwin Biopharm Holdings

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company also develops animal medicines; engaged in the p... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 6617
Full Company Profile

Financial Performance

In 2024, Gongwin Biopharm Holdings's revenue was 32.04 million, an increase of 69.39% compared to the previous year's 18.92 million. Losses were -82.55 million, -10.31% less than in 2023.

Financial Statements

News

There is no news available yet.